
Pembrolizumab Plus Chemotherapy Led to Pathological Complete Response in Patients with Breast Cancer
The trial was recommended to continue to analyze event-free survival rates, but current results are encouraging for treating estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.




























